TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Area Under the Plasma Concentration-time Curve From Time 0 to Time of the Last Observed Quantifiable Concentration (Clast) (AUC[0-last])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve From Time 0 to Infinite Time AUC (infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone Erosion volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Survival to Hospital Discharge With Satisfactory Function
Endpoint domain: Mortality/survival
Primary endpoint: Safety of HBN-1
Endpoint domain: Adverse events/effects
Primary endpoint: Attendance at Scheduled Appointments
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in CombiWISE progression rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Specific Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Dynamic MRI measures of in vivo tissue velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Frequency of patients with cancer and cirrhosis
Endpoint domain: Mortality/survival
Primary endpoint: Frequency and incidence of revisions, complications and adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Alive at day 28
Endpoint domain: Mortality/survival
Primary endpoint: Change in cerebral metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Dose normalised area under the curve (AUC/actual dose)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive Inhibition Interference Index
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Subjective Vitality
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Oseltamivir Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aggregate Measure of Guideline-Based Clinical Care Gaps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline for HRQL Total Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change From Baseline in CCIS Score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change From Baseline in the Number of CISC/Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of sleep apnea-hypopnea syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Response rate (Partial and Complete Response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Risk stratification using cT1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Changes in Pupillary Dilation Reflex AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of patients able to start continuation therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants With Local Reactions Within 7 Days After Dose
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Systemic Events Within 7 Days After Dose
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Serious Adverse Events (SAEs) From Dose 1 to End of the Study
Endpoint domain: Adverse events/effects
Primary endpoint: Average glandular dose administered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Image quality: radiographers' scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Image quality: radiologists' scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in QTcP Intervals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Vocal cord granuloma improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change from baseline in pelvic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change from baseline in dysmenorrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FEV1% difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Orientation score from MMSE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sum of free and cued recall from FCSRT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Digit symbol substitution test score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Renin production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: reduction in tremors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in blood metabolite profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in help-seeking behavior
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline in help-outreach behavior
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Timed 360° turn test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MEPD of single agent decitabine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MTD of valproic acid in combination with decitabine
Endpoint domain: Adverse events/effects
Primary endpoint: MEPD of valproic acid and decitabine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicities of single agent decitabine and combination with valproic acid
Endpoint domain: Adverse events/effects
Primary endpoint: Test of Upper Limb Apraxia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants With Any Solicited Administration Site Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Any Solicited Systemic AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Humoral Immune Response in Terms of Neutralizing Antibody Titers Against Respiratory Syncytial Virus (RSV)-Serotype A
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: sensitivity/specificity for lung ventilation detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: correlation ventilation volume - impedance change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction of elevated levels of blood lactate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Nocturnal FFA Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cranio facial pain and disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Global Functioning Scale: Social
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Global Functioning Scale: Role
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Need for invasive mechanical ventilation or death
Endpoint domain: Mortality/survival
Primary endpoint: Lymphatic propulsive velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lymphatic propulsive frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent extravascular dye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vessel tortuosity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vessel dilation ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Flow-Mediated Dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Vago-sympathetic activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in bowel pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: 24 Hour Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Rehabilitation LOS (days)
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in Functional International Measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Stroke Impact Scale 3.0
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Numeric rating scale (NRS) of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cannabis Withdrawal Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of children failing treatment
Endpoint domain: Adverse events/effects
Primary endpoint: earlier pathogen detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfactory relief of IBS-related abdominal pain/discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Satisfactory relief of overall IBS-D symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Average # of Cigarettes Per Smoking Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects Who Were Verified Abstinent From Smoking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Smoking Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Likert Scale of Frequency of Asking About Guns
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Cumulative 48-hour postoperative morphine consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: platelet ACC phosphorylation state
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time From First Dose to Symptom Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of provocation test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of score Points resulting from symptom record
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: fel d 1 concentration in cat dander
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fel d 1 concentration in the air
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensory threshold for warm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensory threshold for cold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain thresholds for heat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain thresholds for cold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mechanical touch perception threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline of Veterans RAND 36-Item Health Survey Physical Component Summary Score (PCS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Lipid biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: APOE lipidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum tolerated total dose of stereotactic body radiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change at Achilles Tendon Cross Sectional Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change at Achilles Tendon Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Objective mask leak data measurement (System Leak)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective Measurement of leak
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Peak Nicotine Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Brain Regions With a Change in Brain Activity Relative to Saline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: ETDRS Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Receptor occupancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain measured in Visual Analog Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total kidney volume (TKV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Xerostomia = grade 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cocaine Abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADHD Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of thrombocytopenia-induced chemotherapy dose modification
Endpoint domain: Adverse events/effects
Primary endpoint: Change in migraine frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient retention rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Dietary adherence rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adverse Events (AEs) of special interest
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity of V/Q PET/CT for PE diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of V/Q PET/CT for PE diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to First Occurrence of Death from Cardiovascular Causes
Endpoint domain: Mortality/survival
Primary endpoint: Average Daily Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver R2* vs LIC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Time Curve for Tenofovir, Emtricitabine and Efavirenz
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Concentration for Tenofovir, Emtricitabine and Efavirenz
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Respiratory Depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Opioid Requirements (Morphine Equivalents)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in morning urine sodium/potassium ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: increased distance in a six minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of newborns who have ROP progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmological outcomes
Primary endpoint: Number of newborns who need surgical treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma concentrations of propranolol at the steady state measured by dried blood spots
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Digit Span
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Box and block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Physical functioning
Primary endpoint: Quantification of Compliance Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: User perception survey
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pre-transfusion splanchnic oxygenation pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-transfusion splanchnic oxygenation pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensory symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuropsychological alterations in MCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cerebral morphological alterations in MCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cerebral functional alterations in MCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prostate-specific antigen (PSA) response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in mIgE B cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of Treatment-emergent Adverse Events (TEAEs) in healthy male participants
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Treatment-emergent Adverse Events (TEAEs) in participants with Parkinson's Disease
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in Cortisol Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Hepatitis D antibodies (Ab)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum Concentrations of Tapentadol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Concentrations of Tapentadol-O-glucuronide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frailty assessment using Kihon Checklist
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frailty assessment using Fried's Frailty Phenotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frailty assessment using Edmonton Frailty Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frailty assessment using Frail Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frailty assessment using Tilburg Frailty Indicator
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of treatment-emergent serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Reads of Treponema pallidum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Tumoral Blood Flow Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of time spent in semirecumbent position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in microbiota composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nature and incidence of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Consistency of headache response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 3 or Higher Toxicity Incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Chronic Effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute Safety
Endpoint domain: Adverse events/effects
Primary endpoint: Chronic Safety
Endpoint domain: Adverse events/effects
Primary endpoint: Time-weighted Mean Change From Baseline Plasma HIV-RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of attended primary care medical appointments
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Trismus prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of serious adverse reactions (SARs)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of important medical reactions (IMRs)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of severe solicited adverse reactions (ARs)
Endpoint domain: Adverse events/effects
Primary endpoint: Participants With Dose Limiting Toxicity (DLT) Rate Less Than or Equal to 33%
Endpoint domain: Adverse events/effects
Primary endpoint: Overall Best Response Rate for Arm A and Arm B
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shaken baby syndrome knowledge level
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Variations in femur morphology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Overall Response
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Collection of DNA and frozen lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Subjects Seropositive for HI Antibodies Against H1N1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects Seroprotected for HI Antibodies Against H1N1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Geometric Increase (MGI) in HI Antibody Titers Against H1N1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 2-hour Postprandial Glucose Incremental Area Under the Curve (IAUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: VAS Pain Score at 24 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS Pain Score at 48 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes